CY1124334T1 - Διαδικασιες για τη συνθεση ενωσεων διαρυλοθειοϋδαντοϊνης και διαρυλυδαντοϊνης - Google Patents

Διαδικασιες για τη συνθεση ενωσεων διαρυλοθειοϋδαντοϊνης και διαρυλυδαντοϊνης

Info

Publication number
CY1124334T1
CY1124334T1 CY20211100657T CY211100657T CY1124334T1 CY 1124334 T1 CY1124334 T1 CY 1124334T1 CY 20211100657 T CY20211100657 T CY 20211100657T CY 211100657 T CY211100657 T CY 211100657T CY 1124334 T1 CY1124334 T1 CY 1124334T1
Authority
CY
Cyprus
Prior art keywords
compounds
procedures
synthesis
diarylythiohydantoine
diarylydantoine
Prior art date
Application number
CY20211100657T
Other languages
English (en)
Inventor
Andrew Thompson
Carol Lamberson
Scott Greenfield
Rajendra Parasmal Jain
Remy Angelaud
Original Assignee
Medivation Prostate Therapeutics Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medivation Prostate Therapeutics Llc filed Critical Medivation Prostate Therapeutics Llc
Publication of CY1124334T1 publication Critical patent/CY1124334T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/72—Two oxygen atoms, e.g. hydantoin
    • C07D233/74—Two oxygen atoms, e.g. hydantoin with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to other ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/86—Oxygen and sulfur atoms, e.g. thiohydantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • C07C231/12—Preparation of carboxylic acid amides by reactions not involving the formation of carboxamide groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
    • C07C237/30—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having the nitrogen atom of the carboxamide group bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems

Abstract

Παρέχονται διαδικασίες για τη σύνθεση ενώσεων διαρυλοθειοϋδαντοΐνης και διαρυλυδαντοΐνης, όπως είναι οι ενώσεις του τύπου: όπου τα Χ, Υ1, Υ2, R1 και R2 είναι όπως ορίζονται στο παρόν. Τα φαρμακευτικά προϊόντα που περιέχουν αυτές τις ενώσεις έχουν ιδιαίτερη χρήση στη θεραπεία του καρκίνου του προστάτη, συμπεριλαμβανομένου του ανθεκτικού στον ευνουχισμό καρκίνου του προστάτη ή/και του ορμονοευαίσθητου καρκίνου του προστάτη.
CY20211100657T 2010-02-24 2021-07-20 Διαδικασιες για τη συνθεση ενωσεων διαρυλοθειοϋδαντοϊνης και διαρυλυδαντοϊνης CY1124334T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US30779610P 2010-02-24 2010-02-24
PCT/US2011/026135 WO2011106570A1 (en) 2010-02-24 2011-02-24 Processes for the synthesis of diarylthiohydantoin and diarylhydantoin compounds
EP11748095.4A EP2538785B1 (en) 2010-02-24 2011-02-24 Processes for the synthesis of diarylthiohydantoin and diarylhydantoin compounds

Publications (1)

Publication Number Publication Date
CY1124334T1 true CY1124334T1 (el) 2022-07-22

Family

ID=44507217

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20181100501T CY1120207T1 (el) 2010-02-24 2018-05-15 Διαδικασιες για τη συνθεση ενωσεων διαρυλοθειοϋδαντοϊνης και διαρυλυδαντοϊνης
CY20211100657T CY1124334T1 (el) 2010-02-24 2021-07-20 Διαδικασιες για τη συνθεση ενωσεων διαρυλοθειοϋδαντοϊνης και διαρυλυδαντοϊνης

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CY20181100501T CY1120207T1 (el) 2010-02-24 2018-05-15 Διαδικασιες για τη συνθεση ενωσεων διαρυλοθειοϋδαντοϊνης και διαρυλυδαντοϊνης

Country Status (17)

Country Link
US (1) US9174943B2 (el)
EP (2) EP3329775B1 (el)
JP (1) JP5718372B2 (el)
KR (1) KR101514659B1 (el)
CN (1) CN103108549B (el)
BR (1) BR112012021406B1 (el)
CA (1) CA2790924C (el)
CY (2) CY1120207T1 (el)
DK (2) DK3329775T3 (el)
ES (2) ES2880354T3 (el)
HU (2) HUE055051T2 (el)
MX (1) MX2012009782A (el)
PL (2) PL2538785T3 (el)
PT (2) PT3329775T (el)
RU (1) RU2554081C2 (el)
SI (2) SI2538785T1 (el)
WO (1) WO2011106570A1 (el)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7709517B2 (en) 2005-05-13 2010-05-04 The Regents Of The University Of California Diarylhydantoin compounds
UY31432A1 (es) 2007-10-26 2009-05-29 Compuestos de diarilhidantoina
SG10201501202TA (en) * 2010-02-16 2015-04-29 Aragon Pharmaceuticals Inc Androgen Receptor Modulators And Uses Thereof
CN103608333B (zh) 2011-03-10 2016-01-06 苏州开拓药业有限公司 雄激素受体拮抗剂及其用途
WO2013067151A1 (en) * 2011-11-02 2013-05-10 Medivation Prostate Therapeutics, Inc. Treatment methods using diarylthiohydantoin derivatives
KR20150053963A (ko) 2012-09-11 2015-05-19 닥터 레디스 레보러터리즈 리미티드 엔잘루타마이드 다형태 및 그의 제조
CN109897004A (zh) * 2012-09-11 2019-06-18 麦迪威森前列腺医疗有限责任公司 恩杂鲁胺制剂
ES2836424T3 (es) 2012-09-26 2021-06-25 Aragon Pharmaceuticals Inc Antiandrógenos para tratar el cáncer de próstata no metastásico y resistente a la castración
CA2889756C (en) 2012-10-26 2023-03-14 Memorial Sloan-Kettering Cancer Center Thiohydantoin compounds as androgen receptor modulators
JOP20200097A1 (ar) 2013-01-15 2017-06-16 Aragon Pharmaceuticals Inc معدل مستقبل أندروجين واستخداماته
RU2520134C1 (ru) * 2013-02-27 2014-06-20 Общество с ограниченной ответственностью "Авионко" (ООО "Авионко") Замещенные (r)-3-(4-метилкарбамоил-3-фторфениламино)-тетрагидро-фуран-3-енкарбоновые кислоты и их эфиры, способ их получения и применения
WO2014167428A2 (en) * 2013-04-10 2014-10-16 Shilpa Medicare Limited Amorphous 4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)-2-fluoro-n-methylbenzamide
WO2015042029A1 (en) * 2013-09-19 2015-03-26 Glaxosmithkline Llc Combination drug therapy
CN105188699B (zh) * 2013-10-14 2017-04-26 杭州普晒医药科技有限公司 恩杂鲁胺的固态形式及其制备方法和用途
US20160251316A1 (en) 2013-10-31 2016-09-01 Sun Pharmaceutical Industries Limited Process for the preparation of enzalutamide
US20160318875A1 (en) 2013-12-16 2016-11-03 Sun Pharmaceutical Industries Limited Processes and intermediates for the preparation of enzalutamide
CN104803918B (zh) * 2014-01-26 2017-11-10 上海医药工业研究院 恩杂鲁胺的制备方法
CN104803919A (zh) * 2014-01-26 2015-07-29 上海医药工业研究院 用于制备恩杂鲁胺中间体的方法
US9611225B2 (en) * 2014-01-27 2017-04-04 Cadila Healthcare Limited Process for preparation of androgen receptor antagonist
US20170174635A1 (en) 2014-02-13 2017-06-22 Sun Pharmaceutical Industries Limited Process for the preparation of enzalutamide
CN104844521B (zh) * 2014-02-13 2017-08-15 成都伊诺达博医药科技有限公司 抗前列腺癌药物恩杂鲁胺的合成方法
CN104844520B (zh) * 2014-02-13 2017-09-05 成都伊诺达博医药科技有限公司 一种合成恩杂鲁胺的方法
CZ2014232A3 (cs) * 2014-04-07 2015-10-14 Zentiva, K.S. Způsob výroby enzalutamidu
CN103910679B (zh) * 2014-04-23 2016-05-25 杭州新博思生物医药有限公司 一种恩杂鲁胺的制备方法
CN103980141A (zh) * 2014-04-25 2014-08-13 山东大学 恩泽特鲁的合成方法
CN104016924B (zh) * 2014-06-16 2016-04-13 上海鼎雅药物化学科技有限公司 一种“一锅法”合成恩杂鲁胺的方法
RU2557235C1 (ru) * 2014-07-08 2015-07-20 Александр Васильевич Иващенко Замещенные 2-тиоксо-имидазолидин-4-оны и их спироаналоги, противораковый активный компонент, фармацевтическая композиция, лекарственный препарат, способ лечения рака простаты
US20170190670A1 (en) * 2014-07-11 2017-07-06 Shilpa Medicare Limited Improved process for the preparation of enzalutamide
CN105461633A (zh) * 2014-07-31 2016-04-06 江苏豪森药业集团有限公司 恩杂鲁胺的制备方法
CN105367441B (zh) * 2014-08-18 2018-11-06 上海医药工业研究院 用于合成恩杂鲁胺的新化合物
CN105461634A (zh) * 2014-08-19 2016-04-06 江苏豪森药业集团有限公司 恩杂鲁胺的制备方法
US10131636B2 (en) * 2014-10-01 2018-11-20 Laurus Labs Limited Process for the preparation of Enzalutamide
CN104356068A (zh) * 2014-10-30 2015-02-18 杭州新博思生物医药有限公司 恩杂鲁胺新晶型及其制备方法
AU2015364537B2 (en) * 2014-12-19 2020-10-08 Aragon Pharmaceuticals, Inc. Process for the preparation of a diarylthiohydantoin compound
ITUB20151311A1 (it) * 2015-05-28 2016-11-28 Olon Spa Procedimento per la preparazione di enzalutamide
ITUB20151204A1 (it) 2015-05-28 2016-11-28 Olon Spa Procedimento per la preparazione di enzalutamide
ITUB20151256A1 (it) 2015-05-28 2016-11-28 Olon Spa Processo industriale per la preparazione di enzalutamide
EP3305770B1 (en) * 2015-05-29 2023-03-29 Astellas Pharma Inc. Process for producing enzalutamide crystal form
TWI613194B (zh) * 2015-06-10 2018-02-01 台灣神隆股份有限公司 用於製備恩雜魯胺的新穎方法
CN105330560A (zh) * 2015-10-13 2016-02-17 福格森（武汉）生物科技股份有限公司 一种恩杂鲁胺中间体的制备方法
TWI726969B (zh) 2016-01-11 2021-05-11 比利時商健生藥品公司 用作雄性激素受體拮抗劑之經取代之硫尿囊素衍生物
CN107954936B (zh) * 2016-10-17 2021-03-19 海创药业股份有限公司 一种制备氘代咪唑二酮类化合物的方法
CN108069869B (zh) * 2016-11-09 2022-03-01 上海医药工业研究院 一种Apalutamide的制备方法及其中间体
TW201831461A (zh) * 2017-01-18 2018-09-01 台灣神隆股份有限公司 製備阿帕魯醯胺的方法
KR20190137920A (ko) 2017-04-28 2019-12-11 아스텔라스세이야쿠 가부시키가이샤 엔잘루타미드를 함유하는 경구 투여용 의약 조성물
CN107501237B (zh) * 2017-08-17 2022-03-22 上海西浦医药科技有限公司 一种Apalutamide的合成方法
EP3697398A1 (en) 2017-10-16 2020-08-26 Aragon Pharmaceuticals, Inc. Anti-androgens for the treatment of non-metastatic castration-resistant prostate cancer
WO2019106691A1 (en) * 2017-11-28 2019-06-06 Aarti Industries Limited Process for preparation of enzalutamide using novel intermediate
CN108047200A (zh) * 2017-12-05 2018-05-18 上海丰瑞医药科技有限公司 一种二芳基乙内酰硫脲类化合物的制备方法及其中间体
CN109988077A (zh) * 2017-12-29 2019-07-09 上海法默生物科技有限公司 一种阿帕鲁胺的合成方法及中间体
CN110872258B (zh) * 2018-09-04 2021-05-25 北京凯莱天成医药科技有限公司 一种前列腺癌药物恩杂鲁胺的制备工艺
CN109651256A (zh) * 2018-11-20 2019-04-19 上海健康医学院 一种式（viii）的恩杂鲁胺的制备方法
CN109503416A (zh) * 2018-12-24 2019-03-22 常州智超化学有限公司 一种恩杂鲁胺中间体合成方法
CN112047888A (zh) * 2019-06-05 2020-12-08 安礼特（上海）医药科技有限公司 一种合成恩杂鲁胺的方法
CN111320552B (zh) * 2020-02-28 2023-10-27 江西科睿药业有限公司 一种恩扎卢胺中间体的制备方法
CN117120436A (zh) * 2021-03-30 2023-11-24 苏州开拓药业股份有限公司 一种一步法合成乙内酰硫脲衍生物的方法
EP4112603A1 (en) 2021-06-29 2023-01-04 Química Sintética, S.A. Processes for the preparation of non-steroidal antiandrogens
CN113698310B (zh) * 2021-08-20 2023-03-17 江西金丰药业有限公司 一种恩杂鲁胺双酯中间体的制备方法
CN114591246A (zh) * 2022-03-25 2022-06-07 重庆华邦制药有限公司 一种恩扎卢胺的纯化方法
CN114907439B (zh) * 2022-06-29 2023-07-21 云南中医药大学 一种抗癌化合物及其制药用途
CN115181043A (zh) * 2022-07-27 2022-10-14 爱斯特（成都）生物制药股份有限公司 一种连续流制备4-异硫氰基-2-(三氟甲基)苯甲腈的方法
CN115611765A (zh) * 2022-09-30 2023-01-17 重庆华邦胜凯制药有限公司 一种恩扎卢胺中间体的制备方法
CN115536634A (zh) * 2022-10-17 2022-12-30 上海博悦生物科技有限公司 一种阿帕他胺的合成方法
CN115724759A (zh) * 2022-11-23 2023-03-03 爱斯特（成都）生物制药股份有限公司 一种恩扎卢胺中间体的制备方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2884448A (en) * 1956-07-02 1959-04-28 Gen Aniline & Film Corp Hydrolysis of n-substituted amides
DE1906492B2 (de) * 1969-02-10 1980-07-31 Bayer Ag, 5090 Leverkusen Carbonsäure-Derivate enthaltende Hydantoine und Polyhydantoine
US4424396A (en) * 1982-07-21 1984-01-03 Occidental Chemical Corporation Process for the preparation substituted anilino acids
FR2693461B1 (fr) * 1992-07-08 1994-09-02 Roussel Uclaf Nouvelles phénylimidazolidines substituées, leur procédé de préparation, leur application comme médicaments et les compositions pharmaceutiques les renfermant.
US5235093A (en) * 1992-01-27 1993-08-10 Monsanto Company Process for preparing carboxylic amide ester
FR2823209B1 (fr) * 2001-04-04 2003-12-12 Fournier Lab Sa Nouvelles thiohydantoines et leur utilisation en therapeutique
RU2206326C2 (ru) 2001-04-10 2003-06-20 Асафов Александр Виленович Применение натрия нуклеоспермата для лечения вич-инфекции и способ лечения
EP1790640A4 (en) * 2004-09-09 2009-07-29 Chugai Pharmaceutical Co Ltd NEW IMIDAZOLIDINE DERIVATIVE AND APPLICATION THEREOF
ES2535179T3 (es) * 2005-05-13 2015-05-06 The Regents Of The University Of California Compuesto de diarilhidantoína como antagonistas de los receptores de andrógenos para el tratamiento de cáncer
US7709517B2 (en) 2005-05-13 2010-05-04 The Regents Of The University Of California Diarylhydantoin compounds
DK2368550T3 (da) * 2006-03-27 2013-09-30 Univ California Androgenreceptormodulator til behandlingen af prostatakræft og androgenreceptor-associerede sygdomme
EP2439196A1 (en) 2006-03-29 2012-04-11 The Regents of The University of California Diarylthiohydantoin compounds for use in a method for the treatment of a hyperproliferative disorder
TW200846338A (en) * 2007-02-01 2008-12-01 Chugai Pharmaceutical Co Ltd Pyridyl imidazolidine derivative having sulfamoyl group, and pharmaceutical use thereof
US8461343B2 (en) * 2007-03-27 2013-06-11 Sloan-Kettering Institute For Cancer Research Synthesis of thiohydantoins
UY31432A1 (es) 2007-10-26 2009-05-29 Compuestos de diarilhidantoina
BRPI0820696A2 (pt) * 2007-12-20 2019-09-24 Hoffmann La Roche hidantoínas substituídas como inibidores de cinase de mek
RU2548918C2 (ru) * 2009-02-24 2015-04-20 Медивэйшн Простейт Терапьютикс, Инк. Специфические соединения диарилгидантоина и диарилтиогидантоина
WO2010118354A1 (en) * 2009-04-09 2010-10-14 Medivation Prostate Therapeutics, Inc. Substituted di-arylhydantoin and di-arylthiohydantoin compounds and methods for use thereof

Also Published As

Publication number Publication date
BR112012021406B1 (pt) 2021-08-10
CN103108549A (zh) 2013-05-15
PL3329775T3 (pl) 2021-11-08
US9174943B2 (en) 2015-11-03
RU2554081C2 (ru) 2015-06-27
PL2538785T3 (pl) 2018-08-31
BR112012021406A2 (pt) 2018-06-05
SI3329775T1 (sl) 2021-09-30
MX2012009782A (es) 2012-11-29
CN103108549B (zh) 2015-09-09
ES2671343T3 (es) 2018-06-06
JP2013520519A (ja) 2013-06-06
WO2011106570A1 (en) 2011-09-01
EP2538785A4 (en) 2013-10-30
CA2790924C (en) 2016-08-02
PT2538785T (pt) 2018-05-09
HUE038637T2 (hu) 2018-12-28
BR112012021406A8 (pt) 2018-07-31
KR20130027468A (ko) 2013-03-15
KR101514659B1 (ko) 2015-04-23
EP3329775B1 (en) 2021-04-21
HUE055051T2 (hu) 2021-10-28
PT3329775T (pt) 2021-07-19
DK3329775T3 (da) 2021-07-26
JP5718372B2 (ja) 2015-05-13
CY1120207T1 (el) 2018-12-12
RU2012140454A (ru) 2014-03-27
CA2790924A1 (en) 2011-09-01
DK2538785T3 (en) 2018-05-22
EP2538785B1 (en) 2018-03-21
ES2880354T3 (es) 2021-11-24
SI2538785T1 (en) 2018-05-31
EP3329775A1 (en) 2018-06-06
US20130190507A1 (en) 2013-07-25
EP2538785A1 (en) 2013-01-02

Similar Documents

Publication Publication Date Title
CY1124334T1 (el) Διαδικασιες για τη συνθεση ενωσεων διαρυλοθειοϋδαντοϊνης και διαρυλυδαντοϊνης
CY1119006T1 (el) Ινδολια
CY1118547T1 (el) Νεα παραγωγα ινδολιζινης, μεθοδος παρασκευης τους και φαρμακευτικες συνθεσεις οι οποιες τα περιεχουν για τη θεραπεια του καρκινου
CY1123991T1 (el) Δικυκλικες ετεροκυκλικες ενωσεις και χρησεις αυτων στη θεραπεια
CY1122984T1 (el) Καρβαμιδικες ενωσεις και μεθοδοι παρασκευης και χρησης τους
CY1121729T1 (el) Παραγωγα αρυλμεθοξυ ισοϊνδολινης και συνθεσεις που περιλαμβανουν αυτα και μεθοδοι χρησης αυτων
CY1120318T1 (el) Υποκατεστημενες βενζυλινδαζολες για χρηση ως αναστολεις κινασης bub1 στη θεραπευτικη αντιμετωπιση υπερπολλαπλασιαστικων ασθενειων
CY1120619T1 (el) Χημικες οντοτητες
CY1119953T1 (el) Yποκατεστημενες πυριδοπυραζινες ως προτυποι syk ανοστολεις
CY1121706T1 (el) Ενωσεις υποκατασταθεισες διυδροϊσοκινολινονης
CY1120287T1 (el) Αναστολεις βρωμιοπεριοχης
CY1118874T1 (el) Ανθρωποποιημενα αντισωματα εναντια στη liv-1 και χρηση αυτων για τη θεραπευτικη αντιμετωπιση του καρκινου
CY1119387T1 (el) Τριαζολοπυραζινες ως αναστολεις brd4 για χρηση στην αντιμετωπιση καρκινου
CY1117105T1 (el) Ενωσεις πυριδαζινονης και χρηση τους ως αναστολεις του daao
MX2018002402A (es) Compuestos de heteroarilo o arilo biciclicos fusionados como moduladores de la quinasa 4 asociada al receptor de la interleucina 1 (irak4).
CY1118129T1 (el) 5-αλκυνυλ-πυριμιδινες
CY1118662T1 (el) Νεες δικυκλικες πυριδινονες
MX2015008196A (es) Imidazopiridinas sustituidas como inhibidores de doble minuto 2 humana.
NZ708382A (en) Cycloalkyl bis-thiadiazole inhibitors of glutaminase and their use as therapeutic agents
PH12015500513A1 (en) Methods for the treatment of locally advanced breast cancer
MX2015001720A (es) Hetero-azepinonas sustituidas.
MX2013010898A (es) Novedoso derivados de la pirimidina.
CY1120355T1 (el) Αναστολεις toy iap
PH12015501088A1 (en) Dimeric compounds
CY1118541T1 (el) D2 αποκλειστες, μεθοδοι συνθεσης και μεθοδοι χρησης